Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
FHTX 
Foghorn Therapeutics Inc (FHTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: FHTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.67
1 Year Target Price $11.67
| 5 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -78.29% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 243.64M USD | Price to earnings Ratio - | 1Y Target Price 11.67 |
Price to earnings Ratio - | 1Y Target Price 11.67 | ||
Volume (30-day avg) 8 | Beta 3.03 | 52 Weeks Range 2.94 - 9.70 | Updated Date 10/17/2025 |
52 Weeks Range 2.94 - 9.70 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.14 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -279.17% |
Management Effectiveness
Return on Assets (TTM) -20.7% | Return on Equity (TTM) -470.38% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 81679059 | Price to Sales(TTM) 10.08 |
Enterprise Value 81679059 | Price to Sales(TTM) 10.08 | ||
Enterprise Value to Revenue 3.38 | Enterprise Value to EBITDA -1.21 | Shares Outstanding 56529969 | Shares Floating 26763549 |
Shares Outstanding 56529969 | Shares Floating 26763549 | ||
Percent Insiders 18.68 | Percent Institutions 72.7 |
Upturn AI SWOT
Foghorn Therapeutics Inc
Company Overview
History and Background
Foghorn Therapeutics Inc. (FHTX) was founded in 2015. It is a clinical-stage biopharmaceutical company discovering and developing a new class of medicines targeting genetically determined chromatin dysregulation to treat cancer. The company's initial focus has been on addressing unmet needs in cancer therapy by modulating the chromatin regulatory system.
Core Business Areas
- Gene Traffic Controlu00ae Platform: Foghorn's proprietary platform discovers and validates novel chromatin targets.
- Drug Discovery and Development: Focused on developing small molecule therapeutics targeting the chromatin regulatory system for oncology.
Leadership and Structure
The leadership team includes key executives focused on research and development, clinical operations, and business development. The organizational structure is typical of a biotech company, with distinct research, clinical, and administrative divisions.
Top Products and Market Share
Key Offerings
- FOG-001 (BRD9 inhibitor): A selective BRD9 inhibitor in Phase 1 dose escalation clinical trial for metastatic uveal melanoma. Competitors include companies developing other targeted therapies for melanoma such as Novartis and Roche.
- FX-5650 (Protein Degrader): Protein degrader for BRM in Phase 1 clinical trial for ARID1A-mutated cancers. Competitors in this space include companies pursuing protein degradation strategies, such as Arvinas and C4 Therapeutics.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and regulatory scrutiny. Oncology is a major therapeutic area with significant unmet needs and strong growth potential.
Positioning
Foghorn Therapeutics is positioned as an innovator in chromatin regulatory system-targeted therapies. Its competitive advantage lies in its proprietary Gene Traffic Controlu00ae platform and focus on genetically determined cancers.
Total Addressable Market (TAM)
The total addressable market for oncology drugs is substantial, projected to be hundreds of billions of dollars. Foghorn is targeting specific sub-segments of the oncology market with high unmet needs. Their TAM is limited by the specific cancer subtypes their therapies target, and would represent only a small percentage of the entire market.
Upturn SWOT Analysis
Strengths
- Proprietary Gene Traffic Controlu00ae platform
- Strong expertise in chromatin biology
- Experienced leadership team
- Early-stage clinical pipeline
- Partnerships with major pharmaceutical companies.
Weaknesses
- Limited clinical data at present
- High cash burn rate
- Dependence on early-stage pipeline success
- Uncertainty of regulatory approval
Opportunities
- Expansion of pipeline with new targets
- Strategic partnerships and collaborations
- Positive clinical trial results
- Potential for breakthrough therapies in underserved markets
Threats
- Clinical trial failures
- Competition from other biotechnology companies
- Regulatory hurdles
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- ARVN
- MDGL
- C4TX
Competitive Landscape
Foghorn competes with other biotech companies in the oncology space. Its advantages include its novel approach to targeting the chromatin regulatory system. Its disadvantages include the risks associated with early-stage drug development.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by expansion of the pipeline and strategic partnerships.
Future Projections: Future growth projections depend on clinical trial outcomes and regulatory approvals. Analyst estimates vary based on the perceived likelihood of success.
Recent Initiatives: Recent initiatives include advancing clinical trials, expanding partnerships, and strengthening the leadership team.
Summary
Foghorn Therapeutics is an early-stage biotech company focused on a novel approach to cancer therapy. The company possesses a strong technology platform and promising early clinical data. However, it faces significant risks inherent in drug development, including clinical trial failures and regulatory hurdles. Its strength is its innovation and the risk comes from its early stage of development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Foghorn Therapeutics Inc. SEC Filings
- Company Website
- Financial News Outlets
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Foghorn Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2020-10-23 | President, CEO & Director Mr. Adrian H. B. Gottschalk | ||
Sector Healthcare | Industry Biotechnology | Full time employees 112 | Website https://foghorntx.com |
Full time employees 112 | Website https://foghorntx.com | ||
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is also developing therapies for mutant cancers, such as androgen receptor, positive prostate cancer, bladder cancer, Non-Small Cell Lung (NSCLC), as well as various lymphomas and leukemias; melanoma, endometrial, gastric, breast, colorectal, and pancreatic cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.